Izeltabart
Modify Date: 2025-08-25 11:39:49
Izeltabart structure
|
Common Name | Izeltabart | ||
|---|---|---|---|---|
| CAS Number | 2642078-60-0 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of IzeltabartIzeltabart (IMGC-936) is a Maytansinoid-based ADC targeting ADAM9. Izeltabart is comprised of a high-affinity humanized antibody site-specifically conjugated to DM21-C, a linker-payload that combines a Maytansinoid microtubule-disrupting payload with a stable tripeptide linker, at a drug antibody ratio of approximately 2.0. Izeltabart exhibits cytotoxicity toward ADAM9-positive human tumor cell lines and has potent antitumor activity in xenograft tumor models[1]. |
| Name | Izeltabart |
|---|
| Description | Izeltabart (IMGC-936) is a Maytansinoid-based ADC targeting ADAM9. Izeltabart is comprised of a high-affinity humanized antibody site-specifically conjugated to DM21-C, a linker-payload that combines a Maytansinoid microtubule-disrupting payload with a stable tripeptide linker, at a drug antibody ratio of approximately 2.0. Izeltabart exhibits cytotoxicity toward ADAM9-positive human tumor cell lines and has potent antitumor activity in xenograft tumor models[1]. |
|---|---|
| Related Catalog | |
| References |
| No Any Chemical & Physical Properties |